The following represents disclosure information provided by authors of this abstract. ASCO's Quality Care Symposium Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-minimization analysis of pemetrexed/carboplatin with maintenance pemetrexed (PemC) versus paclitaxel/carboplatin/bevacizumab with maintenance bevacizumab (PCB) in nonsquamous non-small cell lung cancer (NS-NSCLC).
Christopher N. Graham
Research Funding - RTI Health Solutions
Hediyyih N. Knox
Research Funding - RTI Health Solutions
Katherine B. Winfree
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Lisa M. Hess
Employment or Leadership Position - Lilly
Jingyi Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Waldo Feliu Ortuzar
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ralph Zinner
Research Funding - Lilly